Expedia (NASDAQ: EXPE), PLX Technology Inc. (NASDAQ: PLXT), Corp. Office Properties (NYSE: OFC), Rowan Companies (NYSE: RDC), Forest Labs (NYSE: FRX) and Cincinnati Bell Inc. (NYSE: CBB) ratings and price targets.
ThinkEquity initiated coverage on PLX Technology Inc. (PLXT). They have a "Buy" rating and price target of $4.00 on the firm.
Jefferies Group (NYSE: JEF) cut their price target on Corp. Office Properties (OFC) to $21.00.
Rowan Companies (RDC) was downgraded by Global Hunter Securities from a “Buy” rating to an “Accumulate” rating
Bank of America (NYSE:BAC) lowered its price target on Forest Labs (FRX) from $45.00 to $40.00.
Expedia (EXPE) had its “Neutral” rating reiterated by Goldman Sachs (NYSE: GS).
Piper Jaffray (PJC) initiated coverage on shares of Cincinnati Bell Inc. (CBB). They have a "Neutral" rating on the firm.
Showing posts with label Forest Laboratories. Show all posts
Showing posts with label Forest Laboratories. Show all posts
Friday, December 30, 2011
Tuesday, July 19, 2011
Forest (FRX) (HWD) (MAT) (MON) (MSFT) Reiterated by Analysts
Forest Laboratories, Inc. (NYSE: FRX), Harry Winston Diamond (NYSE: HWD), Mattel, Inc. (NYSE: MAT), Monsanto Co. (NYSE: MON) and Microsoft Corp (NASDAQ: MSFT) reiterated by analysts.
Forest Laboratories, Inc. (FRX) was reiterated a “buy” by Duncan Williams.
Harry Winston Diamond (HWD) was reiterated an “outperform” by Scotia Capital.
Mattel, Inc. (MAT) was reiterated “buy” rating by Citigroup (NYSE:C).
Monsanto Co. (MON) was reiterated an “overweight” rating by Piper Jaffray.
Microsoft Corp (MSFT) was reiterated a “buy” by Citigroup.
Forest Laboratories, Inc. (FRX) was reiterated a “buy” by Duncan Williams.
Harry Winston Diamond (HWD) was reiterated an “outperform” by Scotia Capital.
Mattel, Inc. (MAT) was reiterated “buy” rating by Citigroup (NYSE:C).
Monsanto Co. (MON) was reiterated an “overweight” rating by Piper Jaffray.
Microsoft Corp (MSFT) was reiterated a “buy” by Citigroup.
Thursday, July 14, 2011
News Corp. (NWS) (IBM) (EMC) (FRX) (VMW) Have Ratings Reiterated
News Corporation (NYSE: NWS), IBM (NYSE: IBM), EMC Corp. (NYSE: EMC), Forest Laboratories, Inc. (NYSE: FRX) and VMware, Inc. (NYSE: VMW) had ratings reiterated on them by analysts.
Stifel Nicolaus reiterated a "Buy" rating on EMC Corp. (EMC).
Stifel Nicolaus maintains a "Buy" rating on IBM (IBM).
Citigroup (NYSE:C) reiterated a "Buy" rating on News Corporation (NYSE: NWS). They have a price target of $21.00 on the company.
Wunderlich reiterated a "Hold" rating on VMware, Inc. (VMW).
Citigroup maintains a "Hold" rating on Forest Laboratories, Inc. (FRX). They have a price target of $35.00 on the company.
EMC closed Wednesday at $27.00, gaining $0.07, or 0.26 percent. IBM ended the day at $174.32, rising $0.27, or 0.16 percent. News Corp. closed at $16.36, climbing $0.28, or 1.74 percent. VMware, Inc. closed at $100.28, falling $0.12, or 0.12 percent. Forest Laboratories, Inc. closed at $39.02, up $0.41, or 1.06 percent.
Stifel Nicolaus reiterated a "Buy" rating on EMC Corp. (EMC).
Stifel Nicolaus maintains a "Buy" rating on IBM (IBM).
Citigroup (NYSE:C) reiterated a "Buy" rating on News Corporation (NYSE: NWS). They have a price target of $21.00 on the company.
Wunderlich reiterated a "Hold" rating on VMware, Inc. (VMW).
Citigroup maintains a "Hold" rating on Forest Laboratories, Inc. (FRX). They have a price target of $35.00 on the company.
EMC closed Wednesday at $27.00, gaining $0.07, or 0.26 percent. IBM ended the day at $174.32, rising $0.27, or 0.16 percent. News Corp. closed at $16.36, climbing $0.28, or 1.74 percent. VMware, Inc. closed at $100.28, falling $0.12, or 0.12 percent. Forest Laboratories, Inc. closed at $39.02, up $0.41, or 1.06 percent.
Saturday, May 21, 2011
Price Targets (EXXI) (FRX) (GCI) (GME) (IGTE) Weekly Recap
Price targets on shares of Energy XXI (NASDAQ: EXXI), Forest Laboratories, Inc. (NYSE: FRX), Gannett (NYSE: GCI), GameStop Corp (NYSE: GME) and iGATE Co. (NASDAQ: IGTE) updated by analysts during the last week.
Rodman & Renshaw raised their price target on Energy XXI (EXXI) from $37.00 to $40.00. They have an “outperform” rating on the company.
Jefferies (NYSE:JEF) raised their price target on Forest Laboratories, Inc. (FRX) from $39.00 to $42.00. They have a “buy” rating on the company.
UBS AG (NYSE:UBS) raised their price target on Gannett (GCI) from $16.00 to $25.00. They have a “buy” rating on the company.
Wedbush raised their price target on GameStop Corp (GME) from $26.00 to $33.00. They have an “outperform” rating on the company.
Jefferies raised their price target on iGATE Co. (IGTE) from $22.00 to $26.00. They have a “buy” rating on the company.
Rodman & Renshaw raised their price target on Energy XXI (EXXI) from $37.00 to $40.00. They have an “outperform” rating on the company.
Jefferies (NYSE:JEF) raised their price target on Forest Laboratories, Inc. (FRX) from $39.00 to $42.00. They have a “buy” rating on the company.
UBS AG (NYSE:UBS) raised their price target on Gannett (GCI) from $16.00 to $25.00. They have a “buy” rating on the company.
Wedbush raised their price target on GameStop Corp (GME) from $26.00 to $33.00. They have an “outperform” rating on the company.
Jefferies raised their price target on iGATE Co. (IGTE) from $22.00 to $26.00. They have a “buy” rating on the company.
Monday, May 16, 2011
Price Targets on (EXXI) (FRX) (GCI) (GME) (IGTE) Updated
Price targets on Energy XXI (NASDAQ: EXXI), Forest Laboratories, Inc. (NYSE: FRX), Gannett (NYSE: GCI), GameStop Corp (NYSE: GME) and iGATE Co. (NASDAQ: IGTE) were updated by analysts.
Rodman & Renshaw raised their price target on Energy XXI (EXXI) from $37.00 to $40.00. They have an “outperform” rating on the company.
Jefferies (NYSE:JEF) raised their price target on Forest Laboratories, Inc. (FRX) from $39.00 to $42.00. They have a “buy” rating on the company.
UBS AG (NYSE:UBS) raised their price target on Gannett (GCI) from $16.00 to $25.00. They have a “buy” rating on the company.
Wedbush raised their price target on GameStop Corp (GME) from $26.00 to $33.00. They have an “outperform” rating on the company.
Jefferies raised their price target on iGATE Co. (IGTE) from $22.00 to $26.00. They have a “buy” rating on the company.
Rodman & Renshaw raised their price target on Energy XXI (EXXI) from $37.00 to $40.00. They have an “outperform” rating on the company.
Jefferies (NYSE:JEF) raised their price target on Forest Laboratories, Inc. (FRX) from $39.00 to $42.00. They have a “buy” rating on the company.
UBS AG (NYSE:UBS) raised their price target on Gannett (GCI) from $16.00 to $25.00. They have a “buy” rating on the company.
Wedbush raised their price target on GameStop Corp (GME) from $26.00 to $33.00. They have an “outperform” rating on the company.
Jefferies raised their price target on iGATE Co. (IGTE) from $22.00 to $26.00. They have a “buy” rating on the company.
Thursday, March 10, 2011
Pfizer (PFE), Merck (MRK) About to Die, Along with (NVS), (LLY), (AZN), (GSK), (FRX)?
To say the outlook for big pharma is bleak would be an understatement, as over the next couple years, major patents for key drugs at Pfizer (NYSE:PFE), Merck (NYSE:MRK) Novartis (NYSE:NVS) Eli Lilly (NYSE:LLY) AstraZeneca (NYSE:AZN), GlaxoSmithKline (NYSE:GSK) and Forest Laboratories (NYSE:FRX).
Pfizer (NYSE: PFE) has a huge task cut out for it. The company's blockbuster cholesterol treatment Lipitor, which loses patent protection in November, is the highest-selling drug in the world, and now the company has the tough mission of figuring out how to replicate its success.
Lipitor, launched in 1997, has fetched $10 billion in annual revenues to the company since then. The equation, however, would soon change when generic-drug makers begin selling cheaper versions. Plus, Pfizer's patent for Xalatan glaucoma drug also expires in 2011. So what's a huge pharma company to do?
The other victims
Fortunately, Pfizer is not alone in battling patent troubles. Other big pharmaceutical firms are also facing a similar challenge.
Merck's (MRK) asthma drug Singulair goes off-patent in 2012 while Novartis' (NVS) patents on its cancer drug Zometa and hypertension treatment Diovan are set for expiration in 2012. Eli Lilly's (LLY) schizophrenia drug Zyprexa goes off-patent in 2011. AstraZeneca's (AZN) patent on cholesterol drug Crestor is set to expire in 2012. GlaxoSmithKline's (GSK) Avandia and Forest Laboratories' (FRX) Lexapro are also slated to go off-patent next year. In other words, the patent expiration process is simply another reality of doing business in this particular line of work.
For these drugmakers that have relied heavily on their patented offerings to generate revenue, the next few years appear unusually daunting. One estimate suggests a total of more than 10 medicines would start facing generic competition from this year, resulting in a loss of nearly $50 billion in terms of annual sales of all these medicines put together.
Source
Pfizer (NYSE: PFE) has a huge task cut out for it. The company's blockbuster cholesterol treatment Lipitor, which loses patent protection in November, is the highest-selling drug in the world, and now the company has the tough mission of figuring out how to replicate its success.
Lipitor, launched in 1997, has fetched $10 billion in annual revenues to the company since then. The equation, however, would soon change when generic-drug makers begin selling cheaper versions. Plus, Pfizer's patent for Xalatan glaucoma drug also expires in 2011. So what's a huge pharma company to do?
The other victims
Fortunately, Pfizer is not alone in battling patent troubles. Other big pharmaceutical firms are also facing a similar challenge.
Merck's (MRK) asthma drug Singulair goes off-patent in 2012 while Novartis' (NVS) patents on its cancer drug Zometa and hypertension treatment Diovan are set for expiration in 2012. Eli Lilly's (LLY) schizophrenia drug Zyprexa goes off-patent in 2011. AstraZeneca's (AZN) patent on cholesterol drug Crestor is set to expire in 2012. GlaxoSmithKline's (GSK) Avandia and Forest Laboratories' (FRX) Lexapro are also slated to go off-patent next year. In other words, the patent expiration process is simply another reality of doing business in this particular line of work.
For these drugmakers that have relied heavily on their patented offerings to generate revenue, the next few years appear unusually daunting. One estimate suggests a total of more than 10 medicines would start facing generic competition from this year, resulting in a loss of nearly $50 billion in terms of annual sales of all these medicines put together.
Source
Thursday, January 20, 2011
Forest Laboratories (NYSE:FRX) Looks Dismal After Lexapro
No spin can remove the impact of losing Lexapro's patent to expiration in March 2012.
Barclays says, "Outlook and investment thesis remain unchanged following Forest's 3Q11 report yesterday. Supporting our view, despite the sizable 3Q11 EPS beat - significantly lower-than-expected operating spend having driven most of the positive surprise and the long-term outlook for SG&A and R&D having changed only modestly versus previous expectations, suggesting unlikely change to trough EPS following Lexapro's patent expiry in March 2012. This is consistent with management's longstanding plan to maintain sales/marketing/promo spend post-Lexapro patent expiry, supporting new product pipeline launches.
"Nevertheless, magnitude of earnings required to fill the projected hole with Lexapro's patent expiry remains large. Even assuming successful commercialization of Forest's late-stage development pipeline, we estimate FY13 EPS at $1.09 -- a sharp drop from our revised FY12 estimate of $4.22. Revisiting our Equal Weight/Neutral rating may require more meaningful drivers beyond current expectations for pipeline opportunities."
Barclays maintains an "Equalweight" rating on Forest Laboratories (FRX), which closed Wednesday at $31.88, down $0.38 or 1.18 percent. Barclays did increase their price target on Forest from $37 to $38 for now.
Barclays says, "Outlook and investment thesis remain unchanged following Forest's 3Q11 report yesterday. Supporting our view, despite the sizable 3Q11 EPS beat - significantly lower-than-expected operating spend having driven most of the positive surprise and the long-term outlook for SG&A and R&D having changed only modestly versus previous expectations, suggesting unlikely change to trough EPS following Lexapro's patent expiry in March 2012. This is consistent with management's longstanding plan to maintain sales/marketing/promo spend post-Lexapro patent expiry, supporting new product pipeline launches.
"Nevertheless, magnitude of earnings required to fill the projected hole with Lexapro's patent expiry remains large. Even assuming successful commercialization of Forest's late-stage development pipeline, we estimate FY13 EPS at $1.09 -- a sharp drop from our revised FY12 estimate of $4.22. Revisiting our Equal Weight/Neutral rating may require more meaningful drivers beyond current expectations for pipeline opportunities."
Barclays maintains an "Equalweight" rating on Forest Laboratories (FRX), which closed Wednesday at $31.88, down $0.38 or 1.18 percent. Barclays did increase their price target on Forest from $37 to $38 for now.
Subscribe to:
Posts (Atom)